Press Release

NMT Medical, Inc. (NASDAQ: NMTI) today announced the completion of its Scientific Advisory Board (SAB), which is composed of eight industry leading experts from the cardiovascular and neurological medical communities. The SAB will meet periodically with our scientific and development personnel as well as members of the Company’s executive management to discuss and advise the Company on its ongoing and future clinical, regulatory and development programs, including its pivotal patent foramen ovale (PFO)/stroke and transient ischemic attack trial, CLOSURE I.

“We are honored to have the advice and support of an esteemed group of leaders from the medical community,” said NMT President and Chief Executive Officer Frank Martin. “With CLOSURE I data analysis set to commence in April, it is important that we work closely with our advisors. We will look to the members of the SAB for valuable clinical, medical, and scientific guidance. The Company will benefit from their support and input as we approach the final stages of CLOSURE I and prepare to submit a PMA to the U.S. Food and Drug Administration later this year.”

The eight Scientific Advisory Board members will act as consultants to NMT. Each Board member was chosen for their extensive background in structural heart repair. The members of the board are:

• Lee Benson, MD, Director, Cardiac Diagnostic and Interventional Unit, Division of Cardiology, The Hospital for Sick Children, Toronto, Canada
• Daniel F. Hanley, MD, Professor of Neurology, Neurosurgery, and Anesthesiology and Critical Care Medicine, The Johns Hopkins Medical Institutions, Baltimore, MD
• Christian Jux, MD PhD, Head, Pediatric Catheterisation Laboratory, Pediatric Heart Centre Giessen, Giessen, Germany
• Saibal Kar, MD, Director, Interventional Cardiac Research, Cedars-Sinai Medical Center, Los Angeles, CA
• Michael J. Landzberg, MD, Director, Boston Adult Congenital Heart and Pulmonary Hypertension Service, Brigham and Women’s Hospital, Boston, MA
• James E. Lock, MD, Chief, Department of Cardiology, Children’s Hospital Boston, Boston, MA
• Ramon Quesada, MD, Medical Director of Interventional Cardiology, Baptist Cardiac and Vascular Institute, Miami, FL

• Robert Sommer, MD, Director of the Adult Invasive Congenital Heart Services, Center for Interventional Vascular Therapy, New York-Presbyterian Hospital / Columbia University Medical Center, New York, NY.

About NMT Medical, Inc.

NMT Medical is an advanced medical technology company that designs, develops, manufactures and markets proprietary implant technologies that allow interventional cardiologists to treat structural heart disease through minimally invasive, catheter-based procedures. NMT is currently investigating the potential connection between a common heart defect that allows a right-to-left shunt or flow of blood through a defect like a patent foramen ovale (PFO) and brain attacks such as embolic stroke, transient ischemic attacks (TIAs) and migraine headaches. A common right-to-left shunt can allow venous blood, unfiltered and unmanaged by the lungs, to enter the arterial circulation of the brain, possibly triggering a cerebral event or brain attack. More than 32,000 PFOs have been treated globally with NMT's minimally invasive, catheter-based implant technology.

Stroke is the third leading cause of death in the United States and the leading cause of disability in adults. Each year, 750,000 Americans suffer a new or recurrent stroke and an additional 500,000 Americans experience a TIA.

For more information about NMT Medical, please visit www.nmtmedical.com.

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements, including those relating to the timing and outcome of statistical analysis relating to CLOSURE I, involve known and unknown risks, uncertainties or other factors that may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed under the heading “Risk Factors” included in the Management’s Discussion and Analysis of Financial Condition and Results of Operations in the Company’s Annual Report on Form 10-K for the year ended December 31, 2008, Quarterly Report on Form 10-Q for the quarter ended September 30, 2009, and subsequent filings with the U.S. Securities and Exchange Commission.